AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05294302 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping Space
Description: Coping Space is a psychosocial informational website for PCCC.
Study NCT05030428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran sodium 300 mg
Description: Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
Study NCT05030428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
Study NCT06154252 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CABA-201 following preconditioning with fludarabine and cyclophosphamide
Description: Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Study NCT05858034 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Customized activity plan
Description: Clients with identified challenges to successful aging (pre-frail or frail on screening) will be invited to develop an individualized activity plan to increase mobility, strength, and stamina. Plans will combine activities to improve strength (resistance training), balance (balance exercises), and stamina, and establish weekly goals. Resistance bands and pedometers will be provided. Progress will be measured by self-reported adherence to the activity plan at week 2, 4, 8, 12 and 24 (assessed by telephone at weeks 2, 4, 8 and in person at week 12 and 24). Depression questionnaire (PHQ-9), fatigue screen, exhaustion questions, and SF-12, a measure of health-related quality of life, will be administered at baseline, week 12 and 24.
Study NCT05858034 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Customized nutrition plan
Description: Participants with nutritional needs will have the option of meeting with a nutritionist to develop a personalized nutritional plan with a goal of improving diet quality and optimizing caloric intake. Progress will be measured as above.
Study NCT05286879 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient Navigator
Description: Linkage to services for OUD/SUD treatment including MOUD, Hepatitis C virus (HCV) testing and treatment; those not living with HIV infection will be provided access to PrEP services, and those living with HIV will receive assistance with gaining initial or continued access to ART services during the 6-month post-release intervention period
Study NCT05286879 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mobile Health Unit
Description: Participants will receive HIV PrEP/ HIV ART, MOUD, harm reduction services on the MHU and or assistance from a community health worker in linking to appropriate community-based OUD and other medical and behavioral health providers across the 6 month post-release intervention period
Study NCT04752683 — intervention group
Intervention type: OTHER
Intervention: MyBuddy Employee Wellbeing App
Description: The intervention is not being evaluated in this research study.~The MyBuddy app contains five core components to help employees track their wellbeing (assisting employers in managing their employees' wellbeing). The six core components are: (1) a 'Budometer' stress measure (measure to be validated); (2) working from home information and assessment designed to inform employees about the legal requirements and risks they and their employers are subject to when home working; (3) messaging service for employees to contact their HR department or their line manager; (4) a 'Think Room' forum for staff to discuss ideas; (5) an 'Appreciation Page' for staff to show appreciation for their colleagues; and (6) 'my hours this week' log to track the hours they have worked. A seventh element is available for HR departments demonstrating data for the employees (employees are aware that HR will be able to see their data).
Study NCT04206059 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: A non-contrast brain MRI will be acquired for localizing EEG slow waves
Study NCT04206059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing (QST)
Description: Quantitative sensory testing (QST) using increasing ramp thermal stimulation (32-52 ºC) will be delivered to compare arousal thresholds between conditions.
Study NCT05172154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GlowTest COVID-19 Antigen Home Test Kit
Description: The Arion Bio GlowTest COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection
Study NCT05756998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) (classic technique)
Description: During CS , placement of CuT380 IUD at the top of the uterine fundus with ring forceps or manually; before closing the uterine incision, the strings were placed in the lower uterine segment. If the cervix was closed, dilatation from above with ring forceps or manually. Strings passed through the cervix with ring forceps, then checking that IUD remains at the fundus of the uterus prior to closing the uterine incision. The surgeon took a good care not to include IUD strings within the sutures. Six weeks postpartum; Patients will be questioned for any symptoms of complications or side effects. Pelvic examination (per speculum) and transvaginal ultrasound will be performed. Patient satisfaction will be assessed: pain using (VAS score), missed threads.
Study NCT05756998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) ( New technique)
Description: During CS, the plunger will be removed, the introducer remains in place and the arms of the IUD were released to be in a transverse position. The introducer will be inserted in the cervical canal through the uterine incision, threads might be shortened if needed or if couldn't be advanced into the cervical canal, The introducer containing the IUD will be then pushed upwards , towards the uterine fundus.The IUD will be placed at the uterine fundus and the IUD will be stabilized at its fundal position by grasping the fundus between the thumb anteriorly and the other fingers posteriorly. The uterine incision was closed while the introducer is in situ , then the introducer will be removed vaginally at the end of CS. Six weeks postpartum; Patients will be followed as in the classic technique group.
Study NCT05756998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarian section
Description: Under general or spinal anathesia , the abdomen is opened in layers , the bladder is dissected downwards . The uterus is incised at its lower segment \& the fetus is extracted , followed by the placenta \& membranes . The CU T 380 IUD is inserted either by the classic technique or the standard technique . The uterus is closed in 2 layers by continous non - locked sutures .Proper hemostasis \& closure of the abdomen in layers .
Study NCT05756998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cesarian section
Description: Under general or spinal anathesia , the abdomen is opened in layers , the bladder is dissected downwards . The uterus is incised at its lower segment \& the fetus is extracted , followed by the placenta \& membranes . The CU T 380 IUD is inserted either by the classic technique or the standard technique . The uterus is closed in 2 layers by continous non - locked sutures .Proper hemostasis \& closure of the abdomen in layers .
Study NCT05609578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib oral dose of 400 mg twice daily tablets
Description: oral dose of 400 mg twice daily tablets
Study NCT05609578 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion once every 3 weeks
Study NCT05609578 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemotherapy: Pemetrexed
Description: IV infusion once every 3 weeks
Study NCT05609578 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin
Description: IV infusion once every 3 weeks
Study NCT05227469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: myofunctional therapy
Description: In order to confirm that the exercises are done for a sufficient time and are done correctly, the researcher will take video recordings from the participants and examine these recordings every other day. Respondents will be contacted when errors are detected.
Study NCT06472700 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05145127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: For participants aged ≥12 years 300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.~For participants aged ≥6 to \<12 years is marstacimab 150 mg SC for initial loading dose followed by 75 mg SC QW. 150 mg sc qw is prescribed for participants who meet dose escalation criteria.
Study NCT05195333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The exercise program
Description: The exercise program prepared for the 1st group gestational diabetes will be explained to the pregnant women by the physiotherapist and the exercises will be taught to the patient.
Study NCT05195333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The exercise program
Description: The same exercise program will be given to the participants only as a brochure and they will be asked to do 10 repetitions at home, 3 days a week, until the 34th week of pregnancy.
Study NCT05769608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 12 weeks
Study NCT05769608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorundrostat Dose 1
Description: lorundrostat Dose 1 once daily for 12 weeks
Study NCT05769608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorundrostat Dose 2
Description: lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks for subjects who meet prespecified criteria
Study NCT06176664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low flow oxygen
Description: Standard nasal cannula oxygen up to 2 liters/minute
Study NCT06176664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen
Description: High-flow nasal cannula with heating and humidification up to 2 liters/kilogram/minute
Study NCT05507242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab 210 mg for 20 weeks (5 doses in total, 4-week intervals), administered subcutaneously
Study NCT05507242 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection for 20 weeks (5 doses in total, 4-week intervals)
Study NCT06557161 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: TBI
Description: The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
Study NCT06557161 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TMLI
Description: The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
Study NCT06557161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Study NCT06557161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Study NCT06390163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory-Motor Integration Training
Description: An exercise chain consisting of motor tasks, sensory stimuli and cognitive tasks will be created. Each session will include at least 3 motor tasks, 3 sensory stimuli and 3 cognitive tasks selected according to the patient's condition.
Study NCT04003428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound
Description: HIFU shots will be performed on the placental tissue to produce necrotic lesions of approximately 30% of the total volume. A latency time of 2 minutes between each shot will be observed to avoid the accumulative heat effect, and to ensure optimal positioning of the treatment probe. The maximum duration of the operating time for HIFU shooting shall not exceed 60 minutes.
Study NCT05214118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: technology-based program
Description: Participants will be asked to complete three 25-minute modules covering the transition from pregnancy to postpartum, possible neonatal abstinence syndrome (NAS) or neonatal withdrawal syndrome (NOWS), and interactions with child welfare.
Study NCT04466358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified CLOSE protocol
Description: Modified CLOSE protocol guided isolation of pulmonary veins.
Study NCT04466358 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High density mapping guided pulmonary vein isolation
Description: Modified CLOSE protocol guided isolation of pulmonary veins with additional ablations at sites of gaps or dormant conduction as evidenced by high density mapping of pulmonary vein antra.
Study NCT06028412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sublobar
Description: The minimize unit is the subsegment, the subloar group includes wedge resection, subsegmentectomy, segmentectomy.~It is recommended to perform intraoperative lymph node pathology (not mandatory). If lymph node metastasis is positive, we must switch to lobectomy+system lymph node dissection. lymph node sampling, selective lymph node dissection or systematic lymph node dissection are allowed in this group.
Study NCT06028412 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lobectomy
Description: lobectomy+system lymph node dissection
Study NCT06016608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Angiography, Ocular OCTA, CT Angiography
Description: Magnetic Resonance Angiography of intracranial artery, carotid artery, renal artery and lower extremity artery, CT angiography of coronary artery or intracranial artery
Study NCT04923672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate continuous exercise
Description: Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of continuous moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.
Study NCT04923672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval exercise
Description: Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of intervals of high and moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.
Study NCT05749822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200mg
Description: Fenofibrate 200mg/day
Study NCT05749822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet/ day
Study NCT05749822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: UDCA 13-15mg/kg/day
Study NCT05749822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UDCA
Description: UDCA 13-15mg/kg/day
Study NCT06350110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19- BCMA CAR-T cells
Description: The intervention in this clinical trial involves a novel approach using CD19/BCMA-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD19/BCMA-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD19/BCMA-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD19/BCMA-CAR T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses.
Study NCT06517654 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMG-Biofeedback
Description: The Neurotrac® Simplex device will be used for EMG-Biofeedback treatment. As in the muscle strength assessment procedure, the EMG reference electrode will be placed on the patient\&#39;s forearm, and 2 adhesive electrodes in the EMG channel will be placed on the patient\&#39;s perineal muscles. The patient will be asked to contract and relax the pelvic floor muscles at certain intervals in accordance with the visual and auditory stimuli made on the device screen or computer screen. The pelvic floor muscle contraction and rest period will last 5 seconds each. The program will continue for 2 days a week, 25 minutes per session and 8 weeks and will be performed in a clinical environment. During the treatment, the treatment will be visualized for the patient with different imagery. At the end of the games played, the patients'; scores (%), the lowest and highest EMG values will be recorded in mV. The treatment will be applied to the patients in two sessions per week.
Study NCT06517654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rebound Therapy
Description: The program will be performed in a clinical environment for 8 weeks, 2 days a week, each session will be 30 minutes. The correct breathing pattern will be taught to the patient before starting the exercises. O2 saturation and maximum heart rate will be checked during the rest periods during the exercises. The maximum heart rate will be calculated with the formula (HRmax = 208 - 0.7 × age), and the exercise will be paused when it exceeds 80%. The patient will be asked to contract the pelvic floor muscles during the exercise. Necessary warnings regarding the preservation of posture will be made throughout the exercises. The exercise intensity will be increased progressively in order to ensure the patient's adaptation to the exercises.
Study NCT06517654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program
Description: Home Exercise Program In addition to EMG-Biofeedback Therapy in Group 1, in addition to Rebound Therapy in Group 2, and in Group 3, only a home exercise program will be applied to patients 5 days a week. The exercise program consists of diaphragmatic breathing, piriformis stretching exercise, adductor stretching exercise, gluteal stretching exercise, cat-camel exercise, happy baby position, deep squat exercise, trunk rotator stretching exercises. Each exercise will be repeated 5 times on the right and left, and 20 seconds will be waited for each repetition.
Study NCT05759767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Children in this group will receive medical expulsive therapy in the form of (tamsulosin at a dose of 0.01 mg/kg once daily for 3 weeks after ESWL session.
Study NCT05759767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children in this group will receive placebo once daily for 3 weeks after ESWL session.
Study NCT06107699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Assigned a Patient Navigator to provide information on transitional care and community resources.
Study NCT06567392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] HRS-5965
Description: Patients will receive single dose of orally \[14C\] HRS-5965 on Day 1.
Study NCT04872439 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Patients with autoimmune gastrointestinal dysmotility will provide 20 mL of blood to isolate serum, plasma and peripheral blood mononuclear cells for whole exome sequence. Antibodies to be isolated are: Antineuronal nuclear antibody type 1,Collapsing response-mediator family immunoglobulin G, Ganglionic Acetylcholine Receptor Antibody, Muscle Acetylcholine Receptor Antibody, Striational, Voltage-gated calcium channel, N- type, Voltage-gated calcium channel, P/Q- type, Voltage-gated potassium channel, Glutamic Acid Decarboxylase 65, Gastric parietal cell, Thyroperoxidase, Thyroglobulin
Study NCT05646355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive CRC Screening Outreach
Description: Proactive approach that incorporates a mailed outreach invitation to screen with fecal immunochemical testing (FIT), followed by active assistance to colonoscopy completion if preferred or indicated by FIT test result.
Study NCT05646355 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will not receive additional outreach from the study team regarding CRC screening.
Study NCT06387953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bridge Therapy
Description: After the patient has been intubated in the operating room - the Bridge device intervention will be applied to the subject's ear by a trained study team member. At the time of the pre-incision pause, Initiation of the intervention (Bridge therapy) will begin and will be continued throughout the surgery. The intervention will continue for 24 hours after extubation.